Probleme bei der Darstellung von ARIVA.DE?

  • Laden unsere Charts bei Ihnen nicht?
  • Wird unser Forum bei Ihnen nicht korrekt dargestellt?

Sie nutzen einen Adblocker, der hierfür verantwortlich ist. Hierauf hat ARIVA.DE leider keinen Einfluss. Bitte heben Sie die Blockierung von ARIVA.DE in Ihrem Adblocker auf.

Probleme bei der Darstellung von ARIVA.DE?

Top-Thema

14:18 Uhr
Bieterrennen: Arbeiternehmervertreter in Sorge um Jobs bei Stada

QIAGEN Enhances Bioinformatics Portfolio with Acquisition of OmicSoft

Montag, 09.01.2017 16:20 von

PR Newswire

HILDEN, Germany and GERMANTOWN, Maryland, January 9, 2017 /PRNewswire/ --

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the acquisition of OmicSoft Corporation, providing access to OmicSoft's powerful multi-omics data management infrastructure solution as well as expertly curated 'omics' data sets that complement QIAGEN's bioinformatics portfolio that are relied upon by customers worldwide to gain valuable insights into complex biological data.

OmicSoft is recognized for its suite of cutting-edge software solutions that enable scientists and researchers to efficiently analyze and visualize their own data sets and compare them to massive volumes of publicly available 'omics' data sets - such as The Cancer Genome Atlas (TCGA) operated by the U.S. National Cancer Institute - and share results with colleagues. These solutions, which integrate enterprise access and cloud-based resources, are essential in addressing the rapidly growing need of researchers in discovery and translational research to manage, compare and share the massive volumes of data on DNA, RNA and other biological variables generated with next-generation sequencing (NGS) technologies.

OmicSoft is expected to greatly enhance QIAGEN's industry-leading bioinformatics portfolio by adding key features for the management, analysis and sharing of both primary data and analyzed results, while also expanding the range of QIAGEN's translational and clinical applications.

Click here for full press release

https://www.qiagen.com/about-us/press-releases/pressreleaseview?ID={B26D008F-C0E7-401C-BBA8-7FEF6DD1C448}&lang=en

QIAGEN contacts: 


Investor Relations
John Gilardi           +49-2103-29-11711
Dr. Sarah Fakih        +49-2013-29-11457 
e-mail: ir@QIAGEN.com    
    
Public Relations
Dr. Thomas Theuringer  +49-2103-29-11826
e-mail: pr@QIAGEN.com  

SOURCE QIAGEN N.V.